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Autophagy is a degradation mechanism by which cells recycle cytoplasmic components 
to generate energy. By influencing lymphocyte development, survival, and prolifera-
tion, autophagy regulates the immune responses against self and non-self antigens. 
Deregulation of autophagic pathway has recently been implicated in the pathogenesis 
of several autoimmune diseases, including rheumatoid arthritis (RA). Indeed, autophagy 
seems to be involved in the generation of citrullinated peptides, and also in apoptosis 
resistance in RA. In this review, we summarize the current knowledge on the role of auto-
phagy in RA and discuss the possibility of a clinical application of autophagy modulation 
in this disease.
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iNTRODUCTiON: OveRview ON PHYSiOLOGiCAL FUNCTiONS 
AND MOLeCULAR MeCHANiSM OF AUTOPHAGY
Autophagy is a degradation pathway characterized by the isolation of targeted cytoplasmic mate-
rial in a typical double-membrane vesicle, known as autophagic vacuole or autophagosome (1). 
The subsequent fusion of the autophagosome with the lysosome ensures the correct destruction of 
organelles, misfolded proteins, and microorganisms, carried inside the vesicle. Despite its emerging 
role in human pathology, autophagy is a physiological process involved in basal organelles turnover 
and in the removal of proteins aggregates (2, 3). In response to the condition of cellular stress, such 
as growth factors and nutrients deprivation, intracellular components degraded by autophagy are 
recycled in order to generate ATP and sustain essential cell functions (4). Autophagy is considered 
a pro-survival mechanism, allowing cells to respond to injury by degrading unnecessary and dys-
functional self-components; however, this ability may become a double-edged sword (5). Three types 
of autophagy can be distinguished: macroautophagy, microautophagy, and chaperone-mediated 
autophagy. In this review, we will focus on macroautophagy (hereafter referred to as autophagy), 
which is the most characterized type of autophagy. Considering the crucial role of autophagy in 
Abbreviations: Abs, antibodies; AMBRA1, Beclin-1 regulated autophagy protein 1; anti-CCP, anti-cyclic citrullinated peptide; 
APC, antigen-presenting cells; Atg, autophagy-related genes; BMSCs, bone marrow mesenchymal stem cells; CIA, collagen-
induced arthritis; ER, endoplasmic reticulum; FLS, fibroblast-like synoviocytes; HCQ, hydroxychloroquine; LC3, microtubule-
associated protein 1 light-chain 3; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 
1; MTX, methotrexate; OA, osteoarthritis; PAD, peptidylarginine deiminase; PCs, plasma cells; PE, phosphatidylethanolamine; 
PI3K-III, class III phosphatidylinositol 3-kinase; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor kB 
(NF-kB) ligand; ROS, reactive oxygen species; SLE, systemic lupus erythematosus; TECs, thymic epithelial cells.
FiGURe 1 | Schematic representation of signaling pathways involved in autophagy multistep regulation. Autophagy represents a fundamental physiological  
process, considering its role in ATP production during condition of nutrients deprivation and in controlling organelles and proteins turnover. mTOR complex 1 
(mTORC1), acting as a sensor of energy levels and integrating upstream signals [phosphoinositide 3-kinase (PI3K) and Akt], is one of the most important autophagy 
regulators in cells. In presence of growth factors and hormones, mTORC1 inhibits autophagy activation. On the contrary, in autophagy-activated conditions, the 
repression of mTORC1 activity allows autophagy initiation by ULK1 and PI3K complexes recruited to the just formed phagophore. This pre-autophagosomal 
structure begins to engulf cytoplasmic materials and, thanks to Atg12–Atg5–Atg16L and LC3–phosphatidylethanolamine conjugated systems, it grows up and 
closes to generate the autophagosome. The fusion of the autophagosome with lysosome exposes the cargo to the action of lysosomal hydrolases that degrade 
vesicular content for recycling.
2
Vomero et al. Autophagy and RA
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1577
the maintenance of cellular homeostasis, it is not surprising that 
several signaling-related molecules are involved in the perfect 
functioning of this process. Genetic screens in yeasts allowed the 
discovery of at least 37 autophagy-related genes (Atg) (6). Many 
of these genes, encoding proteins involved in autophagy and 
its regulation, are evolutionarily conserved in humans (7). The 
mammalian target of rapamycin (mTOR) complex 1 (mTORC1) 
regulates the activation of autophagy machinery, acting as a sen-
sor of energy levels and integrating upstream signals deriving 
from other pathways, including the phosphoinositide 3-kinase 
(PI3K)-Akt. As displayed in Figure  1, in the presence of 
aminoacids and growth factors, mTORC1 represses autophagy 
by inhibition of Vps34 and ULK1 complexes. On the contrary, 
in low nutrients state, defined as starvation, the dissociation of 
mTORC1 from the induction complex triggers autophagy (8, 9). 
The autophagosome derives from a double-membrane pre-
autophagosome structure called phagophore, which seems to 
originate from different sources, including plasma membrane 
(10), endoplasmic reticulum (ER) (11), and Golgi complex, 
in mammalian cells (12). Phagophore nucleation requires the 
activity of class III phosphatidylinositol 3-kinase (PI3K-III) 
complex containing Beclin-1 (a mammalian homolog of 
yeast Atg6), hVps34, p150 (a mammalian homolog of yeast 
Vps15), and Atg14-like protein (Atg14L) (13). The autophagy 
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promoting  function of Beclin-1 is influenced by the antiapop-
totic protein Bcl-2; in fact, when Beclin-1 is bound to Bcl-2, 
autophagy is inhibited; instead, the dissociation from Bcl-2 
allows Beclin-1 to interact with PI3K-III complex, and to 
activate autophagy (14). On the contrary, Beclin-1 regulated 
autophagy protein 1 (AMBRA1) is a positive regulator of 
Beclin-1-dependent autophagy; thanks to its capacity to create 
a link between cytoskeletal motor proteins and class III PI3K 
complex (15, 16). Two ubiquitin-like conjugation systems, 
Atg12–Atg5–Atg16L and microtubule-associated protein 1 
light-chain 3 (LC3)–phosphatidylethanolamine (PE), mediate 
the second step of autophagy, which concerns the expansion 
and closure of the autophagosome (17). In the first system, the 
enzymes E1-like Atg7 and E2-like Atg19 promote the covalent 
association of Atg12 to Atg5 (Figure  1). Subsequently, Atg16 
binds to the complex to form the heterotrimer Atg16-Atg12-
Atg5, this organization at the level of the outer portion of 
autophagosomal membrane, mediates the curvature of the 
growing membrane and also participates in the association of 
LC3 to PE (18). LC3 is cleaved by the cysteine protease Atg4 to 
produce the cytosolic form LC3-I, which, after being activated 
by Atg7, is transferred to Atg3 in order to be changed in the 
conjugate form with PE, named LC3-II (Figure  1). LC3-II is 
thus the most commonly used marker to test autophagic acti-
vity, being then the only protein that remains stably associated 
with the autophagosome in maturation (6). Upon being formed, 
the autophagosome fuses with the lysosome to generate the 
autophagolysosome, in which the vesicular content is degraded 
by lysosomal hydrolases. Finally, products of degradation, 
such as aminoacids and lipids, are exported from autophagy-
related compartments to the cytoplasm to be recycled and 
generate new macromolecules (19).
eMeRGiNG ROLeS OF AUTOPHAGY  
iN HUMAN PATHOLOGY
Since the first observation of autophagy, more than 50  years 
ago, there has been a growing interest in studying this mecha-
nism, and deregulated autophagy has been recently connected 
with the pathogenesis of several diseases. Aging is not properly 
considered a disease; however, it is associated with different 
pathological conditions. In the last period of human life, cells 
undergo several changes, including DNA mutations, damages at 
several other molecules, and accumulation of protein aggregates. 
Several studies have demonstrated that autophagy activation 
protects from aging. In fact, not only autophagy levels decrease 
with age but also overexpression of Atg proteins contributes to 
improve life span in a human model of aging in  vitro and in 
mouse models in  vivo (20–22). As already mentioned, one of 
the most important functions of autophagy is the degradation 
of misfolded proteins, so in neurons, the failure of auto-
phagy can contribute to neurodegeneration (23). It can occur in 
Parkinson’s Disease, a neurodegenerative disorder characterized 
by α-synuclein accumulation in the brain. In a study published 
by our group, we demonstrated that autophagy inhibition by 
3-methyladenine (3-MA) and by Atg5 knocking down in lym-
phocytes lead to a significant increase of α-synuclein levels (24).
Moreover, autophagy seems to be linked also to cancer; 
however, this relationship is still controversial. The removal 
of mitochondria, source of reactive oxygen species (ROS), 
performed by autophagy, certainly protects cells from DNA 
mutations and prevents cellular transformation. It has also been 
demonstrated that deletion of the autophagic gene Beclin-1 may 
cause development of various malignancies in mouse models 
(25). Autophagy is also involved in the degradation of intracel-
lular pathogens, which represent a source of proteins involved 
in tumorigenesis (26). Despite its role in the maintenance of 
genomic stability, many studies indicate a tumor-supporting 
function of autophagy, allowing tumor cells to respond to 
stress stimuli, such as nutrients deficiency and hypoxia, thus 
extending their lifespan. Furthermore, it has been demonstrated 
that autophagy-deficient tumors are more sensitive to several 
chemotherapeutic agents (27, 28). In this case, autophagy 
promotes the survival of cancer cells and protects them from 
the action of drugs that induce apoptosis. Although research 
in this field is just at the beginning, an encouraging number of 
works suggest that defects in the autophagy mechanism may 
be involved in the pathogenesis of autoimmune diseases (29). 
In our previous works, we focused on systemic lupus erythema-
tosus (SLE), showing that factors present in the serum of SLE 
patients, probably antibodies, are able to induce autophagy in 
T lymphocytes from healthy donors, but not in T lymphocytes 
from patients with SLE. We speculated that chronic exposure 
to specific autoantibodies, as occurs in SLE, could lead to the 
selection of autophagy-resistant T  lymphocytes (30). Some of 
these autoantibodies could be directed to D4GDI, a regulator of 
Rho proteins activation. More recently, we also identified IgGs 
directed to D4GDI in sera from patients with SLE (31). On the 
contrary, very little is known on the role of autophagy in the 
pathogenesis of rheumatoid arthritis (RA) and other autoim-
mune rheumatic diseases, thus making research on autophagy 
in autoimmune conditions a very intriguing field.
AUTOPHAGY iN AUTOiMMUNiTY AFFAiR: 
ROLe OF AUTOPHAGY iN RA
Rheumatoid arthritis is a chronic autoimmune disease affecting 
not only the joints but also other organs including heart, vascu-
lar system, lungs, and skin. Environmental and genetic factors 
both lead to immune cells activation against self-antigens and 
production of autoantibodies, such as anticyclic citrullinated 
peptide (anti-CCP) antibodies (Abs), pathognomonic markers 
of this disease (32, 33). Several immune cells are involved: T and 
B  cells, macrophages, synovial fibroblasts, chondrocytes, and 
osteoclasts, which lead to the release of different inflammatory 
mediators, sustaining the chronic inflammatory response of the 
disease (34).
Autophagy in immunological Tolerance
Many studies demonstrated autophagy’s contribution to the 
presentation of cytosolic antigens in association with MHC class 
II molecules, playing an important role not only in the acquired 
immune response but also in the maintenance of self-tolerance 
(35). Mechanisms of central (in the primary lymphoid organs) 
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and peripheral tolerance (in peripheral tissues) physiologically 
prevent immune responses to self-antigens (36). During T cells 
development in the thymus, the recognition of peptide–MHC 
molecules on the surface of thymic epithelial cells (TECs) ensures 
that only thymocytes restricted to MHC molecules, and specific 
for non-self (foreign) antigens, will survive and continue their 
maturation.
Emerging evidence indicates that autophagy contributes 
to the maintenance of the central tolerance mechanism (37). 
Mizushima and colleagues (38) found high autophagy levels in 
TECs, suggesting a possible involvement of autophagy in the 
formation of the lymphocytes repertoire during thymic selec-
tion. According to this hypothesis, it was recently revealed 
that there had been an alteration in the selection of the T  cell 
receptor (TCR) restricted to MHC class II in mice transplanted 
with Atg5−/− thymus. Autophagy defects, in association with a 
consequent loss of self-tolerance, could be the reason of multiple 
signs of autoimmunity reported in these animals (39). However, 
Sukseree and colleagues demonstrated that autophagy sup-
pression did not affect the selection of lymphocytes repertoire 
in TECs (40). These two opposite results probably depend on the 
different approach used to inhibit autophagy in the thymus, thus 
further investigations are necessary.
The involvement of autophagy in the presentation of self-
antigens to immature T  cells in the thymus was first analyzed 
by Kasai and colleagues, who showed a colocalization of LC3-II 
with the lysosomal compartment in which MHC–peptide 
complexes are formed (35). More recently, Aichinger et al. dem-
onstrated that autophagy is essential for endogenous antigen-
loading onto MHC class II of TECs for negative selection (41).
Autophagy in Joint Destruction
Although for many years the role of Th1 cells has been consid-
ered predominant in RA, recently, a crucial role of Th17 cells is 
also emerging (42). This cell subset is a primary source of the 
pro-inflammatory cytokine IL-17, which acts in synergy with 
TNF-α and IL-1, contributing to the bone destruction. In this 
context, receptor activator of nuclear factor kB (NF-kB) ligand 
(RANKL) produced by activated T and B cells and fibroblasts, 
by binding to its receptor RANK, expressed in monocyte– 
macrophage lineage, stimulates the differentiation of osteoclast 
precursor cells in mature osteoclasts (43). Most recent findings 
suggest a possible involvement of autophagy in osteoclastogen-
esis. Specifically, hypoxia, which is an autophagy-activating 
stimulus, seems to be able to stimulate maturation of osteoclasts 
(44); moreover, it has been demonstrated that the inhibition 
of autophagy blocked osteoclastogenesis in mouse monocyte/
macrophage cell lines (45). In another work, it has been shown 
that treatment with RANKL caused up-regulation of autophagy 
markers and the knockdown of autophagy substrate p62 
decreased the expression of genes involved in the osteoclas-
togenesis process (46). In experimental arthritis mouse models, 
the inhibition of autophagy reduced signs of bone erosion and 
the number of osteoclasts, suggesting a key role of autophagy in 
bone tissue degradation (47). In this regard, drugs that down-
regulate autophagy may be used to prevent bone resorption in 
RA patients.
Autophagy as a Protective Mechanism 
Against Apoptosis
Autophagy acts promoting cell survival under conditions of 
nutrients deficiency, while apoptosis is a fundamental pro-
grammed cell death mechanism, thus the relationship between 
these two processes influences cell fate. Moreover, through the 
elimination of damaged mitochondria, autophagy also partici-
pates in the reduction of ROS and damaged DNA, thus prevent-
ing the development of apoptosis (48). In several studies in 
which autophagy was suppressed by knocking down autophagy 
genes, cell death was not inhibited, but increased, indicating the 
prominent role of autophagy as a cell survival mechanism (49).
Different molecules are common to both cellular mechanisms. 
As already discussed, family members of Bcl-2, well known 
as apoptosis regulators, are able to modulate also autophagy 
by inhibition of Beclin-1 (14). It has been demonstrated that 
caspase-dependent cleavage of Beclin-1 and its subsequent 
localization to mitochondria promotes the release of proapop-
totic factors from these organelles (50). The balance between 
cell survival and cell death is essential in regulating immune 
cells destiny and it seems to have a crucial role in RA patho-
genesis and progression. One of the most important apoptosis 
functions consists in the extinguishing of inflammation, by 
blocking an excessive immune cells activation and cytokines 
production. In this regard, a reduction of apoptosis rate and 
apoptotic mediators was found at the synovial level, indicating a 
downregulation of apoptosis in RA (51, 52). In fact, RA synovial 
fibroblasts are subjected to a complex pattern of molecular 
changes, including alterations in the expression of signaling 
pathways that lead to an aggressive and invasive phenotype 
(53). The progressive bone and cartilage destruction is attribut-
able to resistance of synovial fibroblasts to apoptosis induction, 
and several intracellular processes, including autophagy, could 
take part in this phenomenon (54). As already discussed, there 
is a controversial crosstalk between autophagy and apoptosis; 
autophagy induction could be a potential mechanism by which 
RA cells protect themselves from apoptosis, increasing thus 
their lifespan. In support of this hypothesis, ER stress caused 
higher autophagy activation in synovial fibroblasts obtained 
from patients with RA than in those from osteoarthritis (OA) 
patients, and RA-fibroblast-like synoviocytes (FLS) appeared 
to be more resistant to cell death induction (55). Moreover, 
an inverse correlation between autophagy and apoptosis in 
synovial tissues from RA patients was found, indicating an 
involvement of autophagy in the apoptosis-resistant phenotype 
of RA synoviocytes (56, 57). Recently, immune-histochemical 
and molecular analysis of autophagy-related molecules on 
synovial biopsies showed increased levels of Beclin1, Atg5, and 
LC3-II in RA compared to OA patients (58). It is important to 
note that TNF-α is not only a potent modulator of inflammatory 
response in RA but also an apoptosis-activator molecule, induc-
ing autophagy in different cell types including skeletal muscle, 
atherosclerotic vascular smooth cells, and also RA synoviocytes 
(59, 60). Connor and co-authors studied the effect of TNF-α on 
protein degradation, demonstrating that in RA synovial fibro-
blasts, TNF-α stimulates the conversion of LC3-I to LC3-II but 
not the activation of proteasome complex (61). A research work 
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by Xu and colleagues revealed a connection between autophagy 
hyperactivation and methotrexate (MTX) resistance, by showing 
that RA-FLS undergo higher levels of MTX-induced apoptosis 
when autophagy is inhibited (62). More recently, in a collagen-
induced arthritis (CIA) rat model, it has been demonstrated 
that inhibition of autophagy alleviated synovial inflammation 
and promoted synovial cell apoptosis through the regulation 
of PI3K/AKT pathway (63). These data confer to autophagy an 
important protective role against apoptosis; for these reasons, 
therapy based on autophagy repression might have a beneficial 
effect in RA.
Autophagy in Lymphocytes Homeostasis
Peripheral immune cells play an important role in the perpetu-
ation of autoimmunity by sustaining systemic inflammation 
status and by participating in the extension of joint destruc-
tion mechanisms. Many studies demonstrated that autophagy 
allows T and B lymphocytes to survive in conditions of nutrients 
deprivation or during stress stimuli (64). Mice lacking Atg5 do 
not survive and have a reduction of peripheral T cells, showing 
how autophagy is essential for their survival (65). Since cyto-
plasmic calcium levels are essential for TCR-signaling pathways 
activation, autophagy-dependent calcium flux regulation could 
influence T  lymphocytes activation. It has been demonstrated 
that CD4+ and CD8+ Atg5−/− cells are not able to properly 
proliferate following TCR stimulation (65). Moreover, the 
inhibition of autophagy causes defects in T  cell activation. 
In fact, deletion of Atg7 results in decreased in IL-2 mRNA level 
and ATP generation, suggesting that autophagy is required to 
ensure appropriate energy level for T  cell activation (66). 
Similar data were obtained also on B lymphocytes, demonstra-
ting that autophagy is essential for the maturation process and 
for the subsequent maintenance of B lymphocytes repertoire in 
the periphery (67, 68).
Systemic autoimmune diseases such as RA are characterized 
by secretion of pathogenic autoantibodies by plasma cells (PCs), 
and an increase of this phenomenon seems to be associated 
with autophagy defects (69). First of all, autophagy seems to 
be involved in “PC differentiation program” since it has been 
found to be activated during this process (70). The absence of the 
autophagic gene Atg5 does not alter B lymphocytes differentia-
tion, but these cells secrete a larger amount of Abs compared to the 
wild-type counterpart (71). On the other hand, the suppression 
of autophagy makes PCs more susceptible to cell death, stopping 
in this way the persistent Abs secretion. Conway and colleagues 
obtained similar results in the same mouse model, underlying 
a crucial role of autophagy in PCs homeostasis (72).
Studies on the role of autophagy in lymphocytes isolated 
from RA patients are scarce and yet contradictory. Yang and 
colleagues explored the metabolic activity of RA T cells, show-
ing a defect of autophagy in these cells related to a deficiency 
of PFKFB3, a regulatory glycolytic enzyme (73). Opposite data 
were recently published by van Loosdregt and co-authors. They 
demonstrated that CD4+ T cells from RA patients treated with 
hydroxychloroquine (HCQ) showed increased levels of LC3-II 
and autophagosomes number compared with cells isolated 
from healthy donors (74). Autophagy hyperactivation was found 
in CIA mouse model both in CD4+ T  cells and at inflamma-
tory sites. Moreover, a reduction of arthritis signs was noticed 
after the animals were injected with the autophagy inhibitor 
HCQ (74).
In conclusion, autophagy could maintain autoreactive T and 
B cells populations sustaining RA chronic inflammatory response, 
but more experimental evidences are needed to confirm this 
hypothesis.
Autophagy and Citrullination
Citrullination, chemical conversion of arginine in citrulline 
by the action of peptidylarginine deiminase (PAD) enzymes 
(75), has a crucial role in RA pathogenesis and the presence of 
autoantibodies directed against citrullinated peptides is often 
associated with a poor prognosis. Anti-CCP Abs target certain 
epitopes of citrullinated autoantigens and have a crucial role 
in RA development due to their pathogenetic potential (76). 
In fact, anti-CCP Abs purified from RA patient is capable of 
causing not only in  vitro differentiation of human osteoclasts 
but also bone loss, when they are injected into mice (77). The 
contribution of autophagy to the presentation of citrullinated 
peptides and to the generation of anti-CCP Abs seems to be 
relevant in RA. Ireland and colleagues showed that antigen-
presenting cells (APCs) need autophagy to successfully perform 
citrullinated proteins presentation, but not the unmodified 
antigens presentation, and this process is stopped following 
autophagy inhibition (78). Moreover, since PAD enzyme was 
found to be expressed in autophagy compartment, and classical 
pro-autophagic stimuli, such as nutrients deprivation, pro-
moted the presentation of citrullinated peptides in B cells, the 
authors thought that citrullination could represent a “biochemi-
cal marker of autophagy” (79). In a more recent study, in FLS 
from RA patients, the levels of some citrullinated protein, such 
as vimentin and α-enolase, increased after treatment with the 
autophagy inducer rapamycin (80). Furthermore, for the first 
time, a direct correlation between LC3-II levels and anti-CCP 
titers was found in monocytes from early active RA patients. 
These experimental evidences highlight that autophagy activa-
tion may participate to the break of self-tolerance by sustaining 
generation of citrullinated peptides.
Oxidative Stress
Production of ROS and reactive nitrogen species is triggered 
by different elements such as metabolism and endogenous 
inflammation, and exogenous factors including UV light and 
ionizing radiation. Despite the physiological production of 
these molecules, their accumulation can be deleterious for cell 
homeostasis, leading to DNA mutation and could stimulate 
different molecular pathways, including NF-kB activation, 
with consequent cytokines production and inflammation (81). 
Furthermore, protein structural changes induced by ROS are 
able to modify “primitive” antigen and to form new peptides 
that can trigger an autoimmune response (82). For these reasons, 
an imbalance in oxidative stress regulation plays a crucial role 
in inflammatory autoimmune disorders also by modulating cell 
fate mechanisms. Mitochondria are the most important source of 
FiGURe 2 | Summary of the possible roles of autophagy in the pathogenesis and progression of rheumatoid arthritis (RA). Autophagy could prevent the 
development of autoimmunity scenario by eliminating intracellular pathogens and maintaining immune cells homeostasis, including regulation of immunological 
tolerance mechanisms. However, once it occurs, autophagy could take part in RA progression in several ways, e.g., participating in perpetuation of autoimmune 
response promoting the survival of inflammatory and autoreactive cells, cytokines production, and presentation of citrullinated antigens.
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ROS and autophagy-mediated mitochondria degradation, called 
mitophagy, ensures correct balance of oxidative species levels 
in cells. However, the relationship between autophagy and 
oxi dative stress seems to be very complex in the context of RA, 
where not only total oxidative status is higher in patients than 
in healthy control but also neutrophils ROS levels correlate 
positively with disease activity (83, 84). Since it has been dem-
onstrated an involvement of ROS in autophagosome formation 
by regulation of Atg4 function (85), ROS-mediated autophagy 
induction could contribute to the resistance of apoptosis found 
in synovial and peripheral RA T cells and to the generation of 
citrullinated peptides in APCs, both these aspects will be impor-
tant to deepen in future studies.
The possible roles of autophagy in RA pathogenesis and pro-
gression are summarized in Figure 2.
TARGeTiNG AUTOPHAGY iN RA 
THeRAPY
Considering the key role of autophagy not only in innate 
and adaptive immune regulation but also in immune sys-
tem cells homeostasis, it is not surprising that autophagy 
modulation might be an attractive therapeutic choice in RA. 
As described in our previous review, rapamycin, an autophagy 
activator with mTOR inhibitory effects, led to a decrease of 
disease activity in a small group of SLE patients refractory to 
traditional treatments (29); at present, a clinical trial is test-
ing the possible use of autophagy modulator in SLE treatment 
(https://clinicaltrials.gov/ct2/show/study/NCT00779194). 
Both in SLE and RA, drugs that are able to modulate 
autophagy, such as CQ and HCQ, are currently in use in the 
clinical practice showing a high effectiveness (86). It has been 
demonstrated that CQ is able to inhibit antigen presentation 
to T  cells (87) and the differentiation of osteoclast precur-
sors into mature osteoclasts in vitro and in vivo (88); in both 
these processes, autophagy is actively involved.
As previously discussed, although TNF-α was found to induce 
autophagy in different cell types directly associated with RA 
pathogenesis, till now, the effect of anti-TNF drugs on autophagy 
has not been investigated. TNF-mediated autophagy may have 
a role in the resistance to apoptosis, well documented in the 
disease, and the blocking of autophagy induction by anti-TNF 
drugs may reactivate apoptosis. This hypothesis is validated 
also by a study of Catrina and colleagues, who demonstrated an 
activation of synovial apoptosis after 8 weeks of treatment with 
either etanercept or infliximab (89, 90).
A future therapeutic approach based on autophagy sup-
pression in RA might include 3-MA, a chemical compound 
that inhibits autophagy at an early stage of autophagosome 
formation, blocking the signaling of PI3K. This pathway has 
been used in experiments to analyze how autophagy inhibi-
tion can lead to beneficial effect in RA, including reduction 
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of citrullinated peptides presentation and the reactivation of 
apoptosis pathways (57). Data on the systemic effect of 3-MA 
are limited, but a recent study showed an atheroprotective 
role of 3-MA, probably related to a downregulation of inflam-
mation, in ApoE-deficient mice (91).
The importance of the balance between autophagy and 
apoptosis in the resistance to treatment in RA patients has 
been recently proposed by Xu and colleagues (62). The authors 
showed that MTX, commonly used in the treatment of RA, 
is able to induce autophagy in synovial cells protecting them 
from apoptosis. In fact, the inhibition of autophagy by Beclin-1 
siRNA caused an increased death of these cells by apoptosis. 
Taking all of these considerations, a therapy based on com-
bination of MTX and an autophagy inhibitor in RA has been 
proposed.
Glucocorticoids have been widely used in the treatment of 
autoimmune disorders for its anti-inflammatory and immu-
nosuppressive action, although one of the dark effects of this 
therapy consists in a substantial risk of bone injury. A recent 
study demonstrated a pro-autophagic effect of glucocorticoid 
on bone marrow mesenchymal stem cells (BMSCs), concluding 
that autophagy activation sustained the proliferative potential 
of BMSCs by protecting them from apoptosis (92). Shen et  al. 
showed that the induction of autophagy by rapamycin blocked 
the dexamethasone-induced apoptosis in meniscal cells, while 
the treatment with the autophagy inhibitor 3-MA increased the 
number of apoptotic cells (93). According to these results, other 
studies on condrocytes suggest a beneficial effect on bone loss 
by induction of autophagy contrasting glucocorticoid-induced 
apoptosis (94).
Abnormalities in PI3K/AKT/mTOR axis have been found 
in active RA patients and the activation of this pathway has 
been associated with an excessive activation, proliferation, 
and survival of T and B cells and apoptosis resistance in RA 
synoviocytes (95). The suppression of mTOR signaling may be 
another way to treat RA by modulating autophagy. In a multi-
center study involving 121 RA patients, it was found that there 
was a greater response to the therapy in the group of patients 
treated with the mTOR inhibitor everolimus plus MTX than 
the MTX alone, suggesting that autophagy modulators may 
be added to standard therapy to increase the effectiveness of 
the therapy (96). This result was corroborated by Cejka and 
colleagues, who found a reduction in osteoclast number and 
bone erosions in TNF-transgenic mice treated with sirolimus 
or everolimus (97). Recently, a clinical trial compared the 
therapeutic response of temsirolimus (CCI-779) at three 
different concentrations with placebo in active RA patients 
(https://clinicaltrials.gov/ct2/show/record/NCT00076206). 
Considering the pleiotropic role of mTOR signaling in cell 
metabolism, it is important to note that the effects of mTOR 
inhibition might not be due as much to autophagy inhibition 
but rather to the shutdown of other related pathways. In fact, 
and not surprisingly, personalized pharmacological mTOR 
blockade has been proposed for the treatment of several non-
immune and immune-related disorders (98). To conclude, 
there are several autophagy modulators in use or under inves-
tigation in the management of RA therapy (Table 1). This list 
includes both inducers and inhibitors of autophagy, reflecting 
the controversial role of this process in the pathogenesis of 
RA. Considering the intricate signaling pathways regulating 
autophagy, the pleiotropic activity of some of these drugs still 
represents the most enigmatic aspect. In fact, by acting on dif-
ferent substrates, they can produce opposite signals associated 
to autophagy activation. Moreover, in  vitro studies revealed 
how experimental conditions, timing, and cell types can influ-
ence autophagy-associated results.
CONCLUSiON AND PeRSPeCTiveS
The introduction of biologic agents has revolutionized the 
clinical approach to RA; however, research of new therapeutic 
targets appears to be essential to improve the response to 
therapy. Autophagy is a crucial physiological process and its 
functions are strictly related to tissue and environmental con-
ditions. Increasing evidences point to autophagy as a driving 
mechanism of autoimmune diseases. In RA, autophagy activation 
was found to be essential for the survival of inflammatory cells 
such as synoviocytes and lymphocytes and has an important role 
in citrullination and osteoclastogenesis. However, repression of 
autophagy could expose patients to premature aging, infections, 
and development of malignancy. Currently, compounds that 
modulate autophagy pathway are approved for the management 
of the disease, but long-term effects must be evaluated in order 
to analyze whether autophagy modulation can interfere with 
other biological phenomena.
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TABLe 1 | Autophagy modulators of clinical relevance in rheumatoid arthritis 
(RA).
Regulators of 
autophagy
Use/not in 
use in RA 
treatment
effects on RA mediated  
by autophagy  
modulation
Reference
inducers
Rapamacin Not in use Promotion of cell survival; 
citrullination
(96–98)
Glucocorticoids In use Chondrocytes apoptosis protection (93, 94)
Methotrexate In use Resistance to RA-FLS apoptosis (62)
inhibitors
Chloroquine In use Inhibition of antigen presentation (87, 88)
3-MA Not in use Reduction of citrullinated peptides 
presentation; apoptosis induction
(57, 91)
Anti-TNF  
drugs (?)
In use Apoptosis reactivation (89, 90)
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